---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-042644"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T09:55:04.584530+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eledon Q4 net loss $44.6M; cash runway extended; tegoprubart used in pig kidney transplant

## Summary
- Q4 2024 net loss $44.6M ($0.64/shr) vs $30.1M ($1.00/shr) in Q4 2023; includes non-cash warrant loss $20.9M.
- FY 2024 net loss $36.2M vs $116.5M in 2023; excluding warrant changes, net loss $67.1M vs $40.3M.
- Cash $140.2M at Dec 31, 2024; $85M oversubscribed offering extends runway to end of 2026.
- Tegoprubart used in second genetically modified pig kidney transplant (Jan 25, 2025) at Mass General; patient off dialysis.
- Positive initial data on islet transplant recipients; insulin independence without tacrolimus; topline Ph2 BESTOW due Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-042644
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017025042644/0000950170-25-042644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017025042644/eldn-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-042644
- JSON: https://secwatch.observer/filing/0000950170-25-042644.json
- Plain text: https://secwatch.observer/filing/0000950170-25-042644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.